Department of Neurology, AIIMS, Delhi
*Address for correspondence: Dr Manjari Tripathi, Professor Neurology, NIH Fellow (UCLA), Department of Neurology, Room No 705, Neurosciences Centre, All India Institute of Medical Sciences, Ansai Nagar, New Delhi, Email: mtripathiaiims@gmail.com
Online published on 21 November, 2016.
Insomnia is one of the most prevalent sleep disorders. Patients with insomnia tend to have altered quality of life, impaired daytime functioning and increased risk of road traffic accidents. Insomnia is commonly associated with chronic medical conditions and psychiatric illness like depression and anxiety. However, it is now being recognized as an independent disorder. All patients of Insomnia should receive therapy for any medical illness, psychiatric disorders, substance abuse or sleep disorders that might precipitate insomnia. In this review, we discuss the current pharmacotherapeutic options for treatment of insomnia. Research for newer therapeutics for insomnia is often complicated by multifactorial etiology. of insomnia. Understanding the molecular and receptor mechanisms involved in promoting sleep may provide further approaches tothe development of newer drugs.
